A review of the pharmacokinetic and pharmacological properties of a once-yearly administered histrelin acetate implant in the treatment of prostate cancer.
Schlegel
Peter
P
Department of Urology, Weill Cornell Medical College, New York, NY 10021, USA. pnschleg@med.cornell.edu
D000042:Absorption; D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage* / Q000493:pharmacokinetics; D001682:Biological Availability; D003692:Delayed-Action Preparations; D004334:Drug Administration Schedule; D004343:Drug Implants; D005640:Follicle Stimulating Hormone / Q000037:antagonists & inhibitors; D007987:Gonadotropin-Releasing Hormone / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000493:pharmacokinetics; D006801:Humans; D007986:Luteinizing Hormone / Q000037:antagonists & inhibitors; D008297:Male; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D013739:Testosterone / Q000037:antagonists & inhibitors
D018931:Antineoplastic Agents, Hormonal; D003692:Delayed-Action Preparations; D004343:Drug Implants; D007987:Gonadotropin-Releasing Hormone; D013739:Testosterone; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone; C029256:histrelin